Close
Smartlab Europe
Inizio Ignite

Lonza Welcomes New Group Chief Executive Officer Pierre-Alain Ruffieux

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Therapeutic Frontiers in Malignant Mesothelioma Management

Malignant mesothelioma is one of oncology’s most challenging diagnoses....

CRO Clinical Trials: Structure and Purpose in Modern Research

Clinical trials require carefully organized processes to ensure that...

AstraZeneca-Modella AI Acquisition to Speed Oncology R&D

AstraZeneca has agreed to acquire Boston-based Modella AI as...
- Advertisement -

Pierre-Alain Ruffieux today joins Lonza Group in the role of Chief Executive Officer. Albert Baehny has taken the role of CEO ad interim since November 2019. He will now work with Pierre-Alain to ensure a smooth handover of leadership before returning to his role as Chairman of the Board of Directors.

Pierre-Alain brings with him more than 20 years of experience in biopharmaceuticals, most recently as Head of Global Pharma Technical Operations at Roche, where he oversaw pharmaceutical commercial manufacturing and supply chain operations.

Pierre-Alain joins Lonza at a significant moment of opportunity, supported by increasing global awareness of the critical industry contribution made by pharma and biotech manufacturing technologies. Lonza is well positioned to capitalize on future opportunities, as it refocuses its attention on long-term business growth, supported by a sustained series of confident CAPEX investments.

Latest stories

Related stories

Therapeutic Frontiers in Malignant Mesothelioma Management

Malignant mesothelioma is one of oncology’s most challenging diagnoses....

CRO Clinical Trials: Structure and Purpose in Modern Research

Clinical trials require carefully organized processes to ensure that...

AstraZeneca-Modella AI Acquisition to Speed Oncology R&D

AstraZeneca has agreed to acquire Boston-based Modella AI as...

Novartis, SciNeuro Brain Shuttle Deal Expands Neuroscience

Novartis has entered into a licensing agreement with SciNeuro...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »